What question did this study set out to answer?

This study aims to clarify the biological mechanism of SR9009 in treating breast cancer using network pharmacology.

April 19, 20260 citationsOpen Access

Network Pharmacology and Molecular Docking to Elucidate the Potential Mechanism of Sr9009 Against Breast Cancer

Key Points

This study aims to clarify the biological mechanism of SR9009 in treating breast cancer using network pharmacology.
Identified 21 targets of SR9009 and compared them with 17,622 known targets of breast cancer.
Analyzed overlapping targets to find common pathways.
Conducted molecular docking to evaluate binding affinity of SR9009 with hub gene targets.
Identified 16 overlapping targets between SR9009 and breast cancer.
Molecular docking analysis demonstrated strong binding affinity of SR9009 with these targets.
Findings suggest potential therapeutic applications of SR9009 in breast cancer treatment.

Abstract

Breast Cancer (BC) is one of the most common malignant tumors. SR9009 Ethyl 3-[[(4-chlorophenyl) methyl-[(5-nitrothiophen-2-yl) methyl amino] methyl] pyrrolidine-1-carboxylate], a specific agonist of pyrrole derivatives has promising pharmaceutical agent and efficacy in treating several conditions including metabolic diseases such as obesity, bipolar, anxiety, depressive disorder and cancer. The goal of this study was to clarify the biological mechanism of SR9009 and develop a prediction target for SR9009 against BC using network pharmacology. We report 16 overlapping targets among 21 targets of SR9009 and 17622 known targets of breast cancer. Resulting, molecular docking analysis shows that SR9009 have affinity binding features with these hub gene targets for further consideration.

AI에게 질문

Bookmark

View Full Paper